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Introduction: Radiation therapy for lung cancer is limited by toxicity 
to normal lung tissue that results from an inflammatory process, lead-
ing to pneumonitis and ﬁbrosis. Soy isoflavones mitigate inflammatory 
inﬁltrates and radiation-induced lung injury, but the cellular immune 
mediators involved in the radioprotective effect are unknown.
Methods: Mice received a single dose of 10 Gy radiation delivered 
to the lungs and daily oral treatment of soy isoflavones. At different 
time points, mice were either processed to harvest bronchoalveolar 
lavage fluid for differential cell counting and lungs for flow cytom-
etry or immunohistochemistry studies.
Results: Combined soy and radiation led to a reduction in inﬁltration 
and activation of alveolar macrophages and neutrophils in both the 
bronchoalveolar and lung parenchyma compartments. Soy treatment 
protected F4/80+CD11c− interstitial macrophages, which are known 
to play an immunoregulatory role and are decreased by radiation. 
Furthermore, soy isoflavones reduced the levels of nitric oxide syn-
thase 2 expression while increasing arginase-1 expression after radia-
tion, suggesting a switch from proinflammatory M1 macrophage to 
an anti-inflammatory M2 macrophage phenotype. Soy also prevented 
the influx of activated neutrophils in lung caused by radiation.
Conclusions: Soy isoflavones inhibit the inﬁltration and activation of 
macrophages and neutrophils induced by radiation in lungs. Soy isofla-
vones-mediated modulation of macrophage and neutrophil responses 
to radiation may contribute to a mechanism of resolution of radiation-
induced chronic inflammation leading to radioprotection of lung tissue.
Key Words: Radiation, Soy isoflavones, Lung inflammation, 
Macrophages, Neutrophils.
(J Thorac Oncol. 2015;10: 1703–1712)
The primary goal of combining a drug modality with radia-tion therapy is to maximize therapeutic beneﬁt while miti-
gating severe off-target side effects in the treatment of patients 
with cancer. Radiation injury to normal lung parenchyma is 
a major concern in non–small-cell lung cancer (NSCLC). 
Radiotherapy given concurrently with chemotherapy is the 
conventional treatment for locally advanced NSCLC present-
ing as unresectable, stage III disease in approximately 50,000 
Americans per year. There is an associated overall 5-year 
survival rate of 20%, emphasizing the need to improve the 
therapeutic ratio of concurrent chemoradiotherapy.1,2 High-
intensity radiotherapy could be more effective but is limited 
by lung tissue toxicity presenting as radiation pneumonitis 
that develops in up to 30% of patients after thoracic radia-
tion.3,4 Radiation pneumonitis is caused by an early inflam-
matory process triggered by damage to lung parenchyma, 
epithelial cells, vascular endothelial cells, and stroma. This 
process involves induction of proinflammatory cytokines and 
chemokines, which recruit inflammatory immune cells to the 
lung tissue resulting in pneumonitis and late ﬁbrosis.5–7 Early 
acute pneumonitis occurs by 2 to 4 months after radiotherapy, 
whereas late chronic pneumonitis manifests clinically over 
6 to 24 months.3,4 At late stages, radiation-induced pulmonary 
ﬁbrosis results from aberrant resolution of inflammation in 
contrast to classic wound-healing processes.6 These adverse 
events after radiotherapy affect patients’ breathing and their 
quality of life. Various strategies to decrease the extent of 
pneumonitis have been investigated but need further research 
efforts.8
We previously explored a complementary approach 
to alleviate lung radiation toxicity using soy isoflavones, 
consisting of genistein, daidzein, and glycitein phytoestro-
gens extracted from soy beans. Although these isoflavones 
are similar in their chemical structure to estrogens, they 
have weak estrogenic activity and act as chemopreventive 
agents.9–11 Our studies demonstrated that soy isoflavones have 
the dual capability of protecting normal lung from radiation 
injury and simultaneously enhancing radiation damage in the 
malignancy.12,13 Soy mitigated the vascular damage, inflam-
mation, and ﬁbrosis caused by radiation injury to lung tis-
sue in a lung cancer model suggesting that soy can alter the 
radiation-induced inflammatory response.12,13 In naive mice, 
DOI: 10.1097/JTO.0000000000000677
Copyright © 2015 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/15/1012-1703
Soy Isoflavones Promote Radioprotection of Normal Lung 
Tissue by Inhibition of Radiation-Induced Activation of 
Macrophages and Neutrophils
Lisa M. Abernathy, PhD,*,† Matthew D. Fountain, MS,*,† Shoshana E. Rothstein, BS,† John M. David, MD†, 
Christopher K. Yunker, BS,† Joseph Rakowski, PhD,† Fulvio Lonardo, MD,‡ Michael C. Joiner, PhD,†  
and Gilda G. Hillman, PhD*,†
*Department of Immunology and Microbiology, †Division of Radiation 
Oncology, Department of Oncology, and ‡Department of Pathology, 
Wayne State University School of Medicine, Detroit, Michigan.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Gilda G. Hillman, PhD, Radiation Oncology 
Division, Department of Oncology, Wayne State University School of 
Medicine, Karmanos Cancer Institute, Hudson Webber Cancer Research 
Center, room 515, 4100 John R., Detroit, MI 48201. E-mail: hillmang@
karmanos.org
ORIGINAL ARTICLE
1704 Copyright © 2015 by the International Association for the Study of Lung Cancer
Abernathy et al. Journal of Thoracic Oncology ® • Volume 10, Number 12, December 2015
soy isoflavones supplementation given prethoracic and post-
thoracic radiation protected the lungs against adverse effects 
of radiation including skin injury, hair loss, increased breath-
ing rates, inflammation, pneumonitis, and ﬁbrosis.14 These 
ﬁndings in naive mice corroborated our ﬁndings in lung tumor 
models and provided evidence for a radioprotective effect of 
soy isoflavones. Importantly, soy isoflavones also sensitized 
cancer cells to radiation both in vivo and in vitro in preclini-
cal tumor models of lung cancer, demonstrating a differential 
effect of radioenhancement on lung tumors with simultaneous 
radioprotection of normal lung tissue.12,13,15
We have reported that supplementation of soy isofla-
vones with thoracic irradiation mitigates radiation-induced 
inflammatory cytokines, inﬁltration of inflammatory cells, 
and ﬁbrosis,12–14 but the cellular mediators of radioprotec-
tion remain unclear. In this study, we investigated the role 
of macrophages and neutrophils in the mitigation of radia-
tion-induced inflammatory events by soy isoflavones in lung 
tissue. Macrophages are recruited as a ﬁrst response to radi-
ation-induced damage in the tumor microenvironment or in 
normal tissues.16 Macrophages play distinct roles in the early 
versus late stages of inflammatory response.17–19 Monocytes 
can differentiate into functionally different macrophage 
subsets. Inflammatory cytokines (tumor necrosis factor-α 
[TNF-α], granulocyte-macrophage colony-stimulating factor, 
interferon-γ) generate classically activated M1 macrophages 
that mediate acute inflammation and participate in Th1 reac-
tions.20 M2 macrophages can be activated by interleukin (IL)-
4, IL-13, IL-10, transforming growth factor-β, or immune 
complexes, participate in Th2 and Treg reactions, and promote 
tumor growth and ﬁbrosis.21,22 M1 predominates during acute 
inflammation, and then switches to M2 during the wound-
healing phase at later stages.21 We tested whether soy influ-
ences macrophage skewing to M1 or M2 subsets, and if this 
altering of macrophage phenotypes could dictate normal lung 
response to radiation-induced damage.
Activation and inﬁltration of neutrophils are a hall-
mark event in the progression of acute lung injury23 and have 
been shown to be involved in radiation-induced alveolitis.24 
Therefore, the effect of soy isoflavones on inﬁltration and acti-
vation status of neutrophils was studied after radiation to the 
lungs. Our ﬁndings suggest that soy can inhibit the inﬁltra-
tion and activation of macrophages and neutrophils induced 
by radiation in lung parenchyma. Radiation induced a proin-
flammatory M1 macrophage phenotype in lungs, while mice 
receiving soy isoflavones and radiation switched to an anti-
inflammatory M2 macrophage subtype. These data indicate 
that soy isoflavones modulate the cellular mediators of the 
inflammatory response induced by radiation.
MATERIALS AND METHODS
Mice
Female BALB/c mice (Harlan, Indianapolis, IN), 
5 to 6 weeks old, were housed in facilities accredited by the 
Association for Assessment and Accreditation of Laboratory 
Animal Care. The animal protocol was approved by Wayne 
State University Institutional Animal Care and Use Committee.
Soy Isoflavones
The soy isoflavone mixture G-4660 used is a pure 
extract of 98.16% isoflavones from soybeans consisting 
of 83.3% genistein, 14.6% daidzein, and 0.26% glycitein 
(manufactured by Organic Technologies (Conshocton, OH) 
and obtained from the National Institutes of Health [NIH], 
Bethesda, MD). The soy isoflavone mixture was dissolved in 
DMSO and mixed with sesame seed oil at a 1:20 ratio just 
before treatment to facilitate gavage and avoid irritation of the 
esophagus by DMSO.12–14
Lung Irradiation
Radiation was delivered to the whole lung. Three anes-
thetized mice, in jigs, were positioned under a 6.4-mm lead 
shield with three cut-outs in an aluminum frame mounted on 
the radiograph machine for selective irradiation of the lung, 
as previously described.13 The dose rate was 101 cGy/minute, 
and half value layer was 2 mm Cu. Photon irradiation was per-
formed at a dose of 10 Gy with a Siemens Stabilipan X-ray 
set operated at 250 kV, 15 mA with 1-mm copper ﬁltration at a 
distance of 47.5 cm from the target.
Experimental Design
Mice were pretreated with oral soy isoflavones for 
3 days at a dose of 5 mg/day (250 mg/kg). Then, the lung was 
selectively irradiated with 10 Gy. Soy treatment was continued 
at 5 mg/day for 10 days and then switched to a lower dose of 
1 mg/day (50 mg/kg), given 5 days a week for up to 18 weeks, 
based on previous studies.12,25 We have reported that these 
doses of soy isoflavones result in plasma levels comparable 
with those measured in Asian populations consuming foods 
rich in soy isoflavones (1–4 μM).14 At different time points, 
mice were either processed to harvest bronchoalveolar lavage 
(BAL) fluid for differential cell counting and lungs for flow 
cytometry or immunohistochemistry studies.
Analysis of Immune Cells by Differential Cell 
Counting in BAL fluid and flow Cytometry 
on Single-cell Suspension from Lungs
BAL was performed before lung resection at 1, 8, 12, 
and 18 weeks after irradiation. Cells were loaded onto slides 
using a cytospin centrifuge and stained using a DiffQuik stain-
ing kit (IMEB Inc., San Marcos, CA,). Differential cell counts 
of leukocyte subsets were performed by counting at least 
300 nucleated cells.26
After collection of BAL fluids, the same mice provided 
the lungs for flow cytometry studies. Lungs were digested with 
0.4 mg/ml collagenase IV, and red blood cells were lysed. Lung 
single-cell suspensions were incubated with Fc receptor-block-
ing antibody (eBioscience, San Diego, CA) before staining. 
For morphological characterization of leukocytes, CD45+ cells 
were sorted by fluorescence-activated cell sorting (FACS) using 
a BD FACSVantage SE. CD45+ cell subsets were gated accord-
ing to cell size and granularity. Cell subsets obtained from each 
gate were spun onto slides using a cytospin and stained using 
a DiffQuik staining kit. To determine immunophenotype, cells 
were immunostained using a 5-color fluorophore combination of 
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antibodies consisting of CD45-APC, CD11b-FITC, F4/80-PE, 
CD11c-APC-eFluor780, and Ly6G-PerCp-Cy5.5 (eBiosci-
ence). Fixable viability dye eFluor450 was used to exclude dead 
cells. Cells were analyzed by flow cytometry using a BD LSR 
II flow cytometer (BD Biosciences, San Jose, CA) followed by 
analysis on FlowJo v10 software (TreeStar, Ashland, OR).
Immunohistochemistry
Lungs were intratracheally instilled with 10% formalin, 
resected, embedded in parafﬁn, and sectioned. Sections were 
incubated with primary antibodies directed against F4/80, nitric 
oxide synthase 2 (NOS2), arginase-1 (Arg-1), Gr-1 (Ly6C/
Ly6G), and myeloperoxidase (MPO) (Abcam, Cambridge, 
United Kingdom) followed by biotinylated secondary antibod-
ies (Vector Labs, Burlingame, CA). Staining was ampliﬁed 
using the avidin–biotin immunoperoxidase technique (Vector 
Labs). All slides were examined on a Nikon E800 microscope. 
Quantitation of the number of macrophages and measure-
ment of cell areas were performed using ImageJ software in 
10 ﬁelds of 40× per slide. For quantitation of overall staining, 
whole slide imaging was performed using a slide scanner and 
DensitoQuant analysis (3D Histech, Perkin Elmer, Hopkinton, 
MA). The percentage of positive area was calculated as the 
number of positive pixels divided by total number of pixels.
Preparation of Lung Tissue Protein 
Lysates and Western Blot Analysis
Protein lysates were prepared from frozen lungs using a 
gentleMACS tissue dissociator (Miltenyi Biotec, San Diego, 
CA). Lung protein extracts (50 μg) were loaded and separated 
on 10% sodium dodecyl sulfate polyacrylamide gel electropho-
resis and transferred to Whatman membranes. Membranes were 
incubated with anti-MPO followed by horseradish peroxidase 
conjugated goat-anti-rabbit secondary antibody (IgG-HRP). 
Membranes were reprobed with anti-β-actin Ab as a loading 
control, visualized by SuperSignal West Pico chemiluminescent 
substrate (ThermoFisher Scientiﬁc, Waltham, MA), and cap-
tured on a Fotodyne imaging system (Fotodyne Incorporated, 
Hartland, WI).15
Statistical Analysis
Comparisons between means of two treatment groups 
were analyzed by two-tailed unpaired Student’s t test. A value 
of p less than 0.05 was considered statistically signiﬁcant.
RESULTS
Effect of Radiation and Soy Isoflavones 
on Immune Cell Subsets Recovered 
from Bronchoalveolar Space
To identify the nature of inflammatory inﬁltrates in lungs 
induced by radiation and the effect of soy isoflavones on these 
cells, we ﬁrst analyzed immune cell subsets recovered from 
BAL.26 Alveolar macrophages constituted 80% to 90% of cells 
recovered from BAL fluids, and the majority presented as small 
macrophages in both control and soy-treated BAL (Fig. 1). At 
1 week after radiation, there was a signiﬁcant decrease from 
90.7 ± 0.8% to 24.1 ± 2.9% in small macrophages compared 
with control (p < 0.0001). A concomitant signiﬁcant increase 
from 9.1 ± 0.7% to 75.8 ± 3.0% in enlarged foamy macrophages 
(p < 0.0001) with a structure typical of activated macrophages 
was observed (Fig. 1A, inset). This trend was consistent at 8, 
12, and 18 weeks after radiation (Fig. 1B–D). At 8, 12, and 18 
weeks after radiation and soy, there was a signiﬁcant increase 
in small macrophages associated with a concomitant decrease 
in enlarged foamy macrophages (p < 0.01) with ratios compa-
rable with those of control mice.
Whereas BAL fluids from control mice have undetect-
able numbers of neutrophils and lymphocytes, neutrophil 
counts showed a signiﬁcant increase induced by radiation at 
12 weeks (19.0 ± 2.1%, p < 0.0001), which was decreased 
in radiation and soy isoflavones–treated mice (8.4 ± 3.2%, 
p < 0.05) (Fig. 1C). A measurable increase in BAL lympho-
cytes was also observed after radiation; however, this increase 
was not seen in radiation and soy–treated mice.
flow Cytometry Phenotypic Analysis 
of Immune Myeloid Cells Infiltrating 
Lung Parenchyma after Treatment 
with Radiation and Soy Isoflavones
Analysis of the bronchoalveolar compartment revealed 
that radiation caused a switch from nonactivated to activated 
macrophages at 2 to 4 months after radiation, which was pre-
vented by soy isoflavones. To further determine the immuno-
phenotype of the cells involved in the soy radioprotection, we 
have analyzed immune cell subsets in the lung parenchyma 
compartment by flow cytometry.
In a ﬁrst step, lung cell suspensions from control mice 
were stained with anti-CD45 to separate and sort leukocytes 
by FACS. Gate G1 contained lymphocytes, gate G2 consisted 
of a majority of neutrophils/granulocytes and a few macro-
phages, and gate G3 was primarily composed of alveolar mac-
rophages and some granulocytes (Fig. 2A). Consistent with 
ﬁndings in BAL, lymphocytes in gate G1 did not show major 
alterations by treatment (personal communications, Abernathy 
and Hillman); therefore, we focused on myeloid cells.
To analyze the phenotype of myeloid cells obtained from 
lungs at 12 weeks after radiation, cells were immunostained for 
CD45, CD11b, F4/80, CD11c, and Ly6G. Gates for CD45+ leu-
kocytes were set as shown in Figure 2A, and myeloid cells from 
gates G2 and G3 were further analyzed for speciﬁc macrophages 
and neutrophil markers. Macrophages were gated based on dif-
ferential expression of F4/80 and CD11c to analyze interstitial 
macrophages (F4/80+CD11c−) and alveolar macrophages (AM, 
F4/80+CD11c+) (Fig. 2B).27 Percentages of F4/80+CD11c− inter-
stitial macrophages subsets showed a signiﬁcant decrease in 
interstitial macrophages induced by radiation compared with 
control (p < 0.05), whereas this treatment with soy isoflavones 
protected this population in irradiated lung tissue (p < 0.05) 
(Fig. 2B). F4/80+CD11c+ AM subsets did not show difference 
between treatments (Fig. 2B), in contrast to BAL ﬁndings that 
showed an increase in AM by radiation and decrease by radiation 
+ soy. The discrepancies between alveolar macrophages in BAL 
fluid and lung tissue compartments could be because of lavage of 
loose alveolar macrophages and subsequent processing of lungs 
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for FACS. Neutrophils were gated by expression of CD11b and 
Ly6G/Gr-1 markers within the CD45+ population (Fig. 2C).28 
CD11b+Ly6G+ neutrophils in lungs are signiﬁcantly increased 
after radiation compared with control (p = 0.01); however, sup-
plementation of soy to radiation did not signiﬁcantly change the 
percent of neutrophils (Fig. 2C).
Skewing Toward Anti-inflammatory M2 
Macrophage Phenotype in Lung Tissue 
Treated with Radiation and Soy
To further study whether soy inhibits the activation 
of macrophages induced by radiation, as suggested in the 
BAL studies, we investigated macrophage subsets and their 
functional status in lungs treated with radiation only and 
radiation + soy. Radiation caused a striking inﬁltration 
of F4/80+ macrophages that was prominent at 18 weeks 
after radiation and observed in areas of thickened alveo-
lar septa, reflective of pneumonitis12–14 (Fig. 3A, arrow-
heads). Numerous alveolar macrophages were particularly 
enlarged with abundant cytoplasm showing the structure of 
activated macrophages compared with small macrophages 
in control lungs (Fig. 3A, see arrows and inset). Lungs from 
mice treated with radiation + soy had a lower density of 
F4/80+ macrophages and thinner alveolar septa (Fig. 3A), 
compared with radiation-treated lungs, showing decreased 
pneumonitis.13,14 Moreover, the morphology of the alveolar 
macrophages was much smaller than those of radiation-
treated lungs (see insets, Fig. 3A). Quantitation of F4/80+ 
cells showed that there was a signiﬁcant increase in the 
number of alveolar macrophages in lungs treated with radi-
ation compared with those in control lungs (p < 0.001, Fig. 
3B). Irradiated mice supplemented with soy isoflavones 
showed a signiﬁcantly reduced number of alveolar macro-
phages compared with radiation alone (p < 0.001, Fig. 3B), 
to levels similar to those of control mice. Measurements 
of the average size of the alveolar macrophages showed 
that radiation increased the size of these cells signiﬁcantly 
compared with either radiation + soy (p < 0.01, Fig. 3C) or 
control (p < 0.0001, Fig. 3C).
To further clarify the functional phenotype of inﬁltrat-
ing macrophages, the NOS2 activation marker for M1 mac-
rophages and Arg-1 activation marker for M2 macrophages 
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fIGURE 1. Effect of soy isoflavones on immune 
cells obtained from bronchoalveolar lavage (BAL) 
fluid at different time points after radiation. BAL flu-
ids were harvested at early and late time points after 
radiation. At 1 week (A), 8 weeks (B), 12 weeks (C), 
and 18 weeks (D) BAL postradiation, differential cell 
counts on BAL fluid cytospins were performed, and 
the percentages of macrophages, neutrophils, and 
lymphocytes were calculated. The ratios of nonacti-
vated macrophages and enlarged, foamy activated 
macrophages (see inset in A), as well as those of 
neutrophils and lymphocytes, are shown from BAL 
fluid obtained from treated and control mice. The 
data are presented as mean ± standard error of the 
mean (n = 3–5 mice/group/time point), and p val-
ues shown represent significant differences between 
radiation + soy compared with radiation alone.  
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, 
radiation compared with control or radiation + soy 
compared with radiation alone.
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were used to differentiate between proinflammatory M1 mac-
rophage phenotype and anti-inflammatory M2 macrophage 
phenotype. Radiation caused a prominent increase in NOS2 
staining of lung tissue by 18 weeks after radiation (Fig. 4A), 
which was apparent in enlarged alveolar macrophages (Fig. 
4A, inset). These ﬁndings were conﬁrmed by slide scanning 
quantitation for the level of staining (Fig. 4B). In contrast, a 
lower level of NOS2 staining was observed after radiation + 
soy (Fig. 4A, B). Staining of lungs with Arg-1 showed a promi-
nent increase in radiation + soy–treated lungs compared with 
radiation alone (Fig. 4C, D).
Radiation caused an increase in proinflammatory M1 
macrophage phenotype deﬁned by high NOS2 and low Arg-1 
levels at 18 weeks after radiation (Fig. 4A, B). This is in con-
trast to relatively low NOS2 levels and high Arg-1 levels 
observed in lungs treated with radiation + soy or in controls 
(Fig. 4B, C).
Radiation-induced Infiltration and Activation 
of Granulocytes/Neutrophils in Lung 
Tissue is Decreased by Soy Isoflavones
Analysis of BAL immune cells showed an increase in 
neutrophils by 12 weeks after radiation. Granulocyte/neutro-
phil phenotype and function were determined by immunohis-
tochemistry staining of lung tissue sections for Gr-1 (Ly6C/
Ly6G) and the neutrophil marker NIMP at 12 weeks after radia-
tion. Radiation caused a pronounced increase in clusters of 
Gr-1+ granulocytes in areas of thickened septa at 12 weeks after 
radiation (Fig. 5, see inset). In contrast, following radiation + 
soy treatment, the alveolar septa were not as thickened and con-
tained much lower levels of Gr-1+ cells (Fig. 5). Staining of lung 
tissue for the neutrophil speciﬁc marker NIMP revealed the 
same histological patterns, with increased neutrophil inﬁltrates 
induced by radiation and decreased by radiation + soy (Fig. 5).
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fIGURE 2. Flow cytometry analysis of macrophages and neutrophils isolated from lung tissues. A, Structure of FACS-sorted 
CD45+ immune cell subsets in normal lung tissue. Normal lungs from untreated mice were dissociated into single-cell suspen-
sions. Cells were immunostained with fluorescent anti-CD45 and sorted by FACS. CD45+ lung leukocyte subsets were gated in 
gates G1, G2, and G3 based on cell size (forward scatter [FSC], x-axis) and granularity (side scatter [SSC], y-axis). Cells in each 
gate were sorted by FACS, cytospun onto slides, and stained with DiffQuik, revealing that gate G1 contained lymphocytes, gate 
G2 consisted of a majority of neutrophils/granulocytes and fewer macrophages, and gate G3 was primarily composed of alveo-
lar macrophages and some granulocytes. All magnifications are at 40×. B, Interstitial and alveolar macrophages analysis.  
At 12 weeks after radiation, lungs from control (Con) mice and mice treated with soy (Soy), radiation (Rad), or radiation + soy 
(R + S) were dissociated into single-cell suspensions. Cells were stained with anti-CD45, anti-F4/80, and anti-CD11c fluorescent 
antibodies to analyze interstitial (F4/80+CD11c−) and alveolar (F4/80+CD11c+) tissue macrophages within CD45+ leukocyte pop-
ulations by flow cytometry. Representative flow cytometry plots are presented, showing the gating strategy of CD45+ myeloid 
lung cells for analysis of F4/80+CD11c− interstitial macrophages (in pink rectangle gate) and F4/80+CD11c+ alveolar macrophage 
(AM in pink circle gate). Percentages of F4/80+CD11c− interstitial macrophages subsets and F4/80+CD11c+ AM subsets within 
CD45+ cells are shown for lungs from control and treated mice. The data are presented as mean ± standard error of the mean 
(n = 4–5 mice/group) and are representative of three separate experiments. C, Analysis of CD45+CD11b+Ly6G+ neutrophils. 
Cells were stained with fluorescent anti-CD45, anti-CD11b, and anti-Ly6G to analyze neutrophil subsets by flow cytometry. 
Representative flow cytometry plots are presented, showing the gating strategy for analysis of CD11b+Ly6G+ neutrophils within 
CD45+ leukocyte populations. Percentages of CD11b+Ly6G+ neutrophils within CD45+ cells are shown for lungs from control 
and treated mice. The data are presented as mean ± standard error of the mean (n = 5 mice/group) and are representative of 
two separate experiments. *p < 0.05, radiation compared with control or radiation + soy compared with radiation alone.
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fIGURE 4. Nitric oxide synthase 2 (NOS2) and arginase (Arg)-1 functional macrophage markers in lungs treated with radia-
tion and soy isoflavones. Lung tissue sections were obtained from control (Con) mice and mice treated with radiation (Rad) or 
radiation + soy (R + S) at 18 weeks after radiation. Sections were stained by immunohistochemistry for the markers NOS2 and 
Arg-1 to determine macrophage activation status in the lungs. A, NOS2 staining revealed an abundance of activated macro-
phages caused by radiation presenting as clusters of enlarged NOS2+ cells in areas of pneumonitis (see insets). Lower levels of 
NOS2+ macrophages were seen in lungs of mice treated with radiation + soy or control, which presented as smaller cells (see 
inset). B, Whole slide scanning for quantitation of NOS2 positive staining confirmed these findings. C, Compared with radiation, 
Arg-1 expression was greater with radiation + soy. D, Whole slide scanning for quantitation of revealed higher levels of Arg-1 in 
radiation + soy compared with low levels after radiation alone. For analysis of whole slide scanning, the percentage of positive 
area was calculated as the total number of positive pixels divided by total number of pixels. All magnifications are at 40× and 
insets at 100× to reveal the extent of positive staining and structure of immune cell subsets.
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sections were obtained from control (Con) mice and mice treated with radiation (Rad) or radiation + soy (R + S) at 18 weeks 
after radiation. Sections were stained by immunohistochemistry for the marker F4/80 to detect alveolar macrophages in the 
lungs. Arrows indicate positive staining of F4/80+ alveolar macrophages. A, Radiation caused a marked increase in macrophages 
in thickened alveolar septa areas (arrowheads). Numerous alveolar macrophages were particularly enlarged with abundant 
cytoplasm showing the structure of activated macrophages compared with small macrophages in control lungs (see inset). The 
density of F4/80+ macrophages was much lower in radiation + soy–treated lungs at 18 weeks after radiation than in radiation-
treated lungs. Alveolar macrophages were smaller, resembling those of control lungs (see inset), and the architecture of the 
alveolar septa was thinner akin to control lung tissue showing decreased pneumonitis compared with radiation-treated lungs.  
B, Using ImageJ analysis of immunohistochemistry slides, the numbers of F4/80+ alveolar macrophages were counted in 10 
fields of 40× per slide and the average number of F4/80+ cells per field ± standard error is reported for each treatment group.  
C, Measurement of the F4/80+ alveolar macrophage cell areas were performed using ImageJ software in 10 fields of 40× per 
slide and the average cell area of macrophages per field ± standard error in each treatment group is reported. The total number 
of macrophages counted and measured in 10 fields were 125 for control, 285 for radiation, and 101 for radiation + soy–treated 
mice. The means are reported in B and C. All magnifications are at 40× and insets at 100× to reveal the extent of positive 
 staining and structure of immune cell subsets. **p < 0.01, ***p < 0.001, ****p < 0.0001, radiation compared with control or  
radiation + soy compared with radiation alone.
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Concurrent with increased inﬁltration of Gr-1+ and 
NIMP+ cells, lungs treated with radiation also showed multiple 
cells with intense MPO staining (Fig. 6). MPO+ cells formed 
clusters in areas of thickened alveolar septa, which are indica-
tive of a massive inﬁltration of activated neutrophils, as con-
ﬁrmed by quantitative analysis of the level of positive staining 
(Fig. 6A and B). However, MPO+ inﬁltrates were reduced in 
lungs treated with radiation + soy (Fig. 6A and B). These data 
indicate that radiation-induced neutrophil activation in lung 
tissue is inhibited by soy isoflavones. These ﬁndings were con-
ﬁrmed by western blot analysis of MPO expression in lung 
tissue lysates showing an increase induced by radiation, which 
was inhibited by the addition of soy isoflavones (Fig. 6C).
DISCUSSION
Conventional fractionated radiotherapy concurrent 
with chemotherapy is currently the standard of care for 
unresectable locally advanced NSCLC. Treatment success 
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fIGURE 5. Effect of soy isoflavones on radiation-induced infiltration of granulocytes/neutrophils in lung tissue. Lungs tissue 
sections were obtained from control (Con) mice and mice treated with radiation (Rad) or radiation + soy (R + S) at 12 weeks 
after radiation. Sections were stained by immunohistochemistry for Gr-1 (Ly6C/Ly6G) and NIMP to detect granulocytes/ 
neutrophils. Staining of Gr-1+ granulocytes showed that radiation caused a pronounced increase in clusters of granulocytes in 
areas of thickened septa at 12 weeks after radiation (see inset). In contrast, after radiation + soy treatment, the alveolar septa 
were not as thickened, and much lower levels of positive cells for Gr-1 were observed. All magnifications are at 40× and insets 
at 100× to reveal the extent of positive staining and structure of immune cell subsets.
Con Rad Rad+Soy
β-actin
MPO
M
PO
Con Rad R+S
0
5
10
15
20
M
PO
po
si
tiv
e
ar
ea
(%
)A
C
B
fIGURE 6. Inhibition of radiation-induced activation of neutrophils in lung tissue. Lungs tissue sections were obtained from 
control (Con) mice and mice treated with radiation (Rad) or radiation + soy (R + S) at 12 weeks after radiation. A and B, 
Sections were stained by immunohistochemistry for the neutrophil activation marker myeloperoxidase (MPO). Radiation caused 
 extensive MPO staining in the lung tissue that is indicative of activated neutrophil infiltration. MPO+ activated neutrophils were 
present in clusters in areas of thickened alveolar septa (see inset) at 12 weeks after radiation. The levels of MPO were greatly 
reduced in radiation + soy–treated lungs. B, Whole slide scanning for quantitation of MPO-positive staining confirmed these 
findings. For analysis of whole slide scanning, the percentage of positive area was calculated as the total number of positive 
pixels divided by total number of pixels. NIMP+ neutrophils were also increased in lung tissue by radiation but not by  
radiation + soy. All magnifications are at 40× and insets at 100× to reveal the extent of positive staining and structure of 
immune cell subsets. C, Western blot analysis of MPO on whole tissue lysates obtained from lungs showed an increase induced 
by radiation, which was inhibited by the addition of soy isoflavones. Band intensities were quantified using Image J (NIH) 
 densitometry analysis.
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for this patient population has been severely constrained by 
pneumonitis and later ﬁbrosis.29,30 Hypofractionated radio-
therapy is an emerging modality for early-stage lung can-
cer using high dose per fraction over a short time period to 
improve effectiveness of tumor destruction and reduce the 
number of visits for therapy.31–33 However, high-intensity 
radiotherapy can also be associated with greater damage to 
lung tissue, emphasizing the need to develop complemen-
tary approaches to alleviate radiation-induced injury to nor-
mal lung structures and function.34 Our preclinical murine 
studies12–14 demonstrate that soy isoflavones can reduce 
the extent of inflammatory inﬁltrates and vascular dam-
age caused by radiation in the lungs, suggesting that soy 
modulates immune responses triggered by injury. Studies 
on the effect of soy and the immune system in other dis-
eases besides cancer also support this hypothesis. Genistein 
downregulated cytokine-induced proinflammatory pathways 
in human brain microvascular endothelial cells.35 Soy isofla-
vones had anti-inflammatory mechanisms through modula-
tion of leukocyte–endothelial cell interactions in the study 
of atherosclerosis.36 The goals of this study were to deter-
mine whether soy isoflavones modulate innate immune cells 
involved in radiation-induced inflammation in normal lungs 
by examining the bronchoalveolar space and lung paren-
chyma compartments.
Macrophages are recruited as a ﬁrst response to radi-
ation-induced damage in the tumor microenvironment.16,37 
Alterations in lung macrophages after radiation have been 
observed during early and late phases of tissue injury38,39 
supporting the idea that macrophage activation contributes, 
at least partially, to the pathogenesis of radiation-induced 
lung injury. Therefore, modulation of the response of mac-
rophages to radiation could be a mechanism of radioprotec-
tion by soy isoflavones. By 2 to 4 months after radiation, 
an increase in the number and size of macrophages was 
observed both in the bronchoalveolar space and lung paren-
chyma compartments, indicative of macrophage activation, 
conﬁrming previous reports.38,39 Soy isoflavones durably 
decreased the frequency and size of macrophages found in 
the lung after radiation.
Our flow cytometry analysis of lung parenchyma after 
lavage identiﬁed subsets of residual F4/80+CD11c+ alveolar 
macrophages and F4/80+CD11c− interstitial macrophages, as 
reported by others.40 A decrease in interstitial macrophages 
was induced by radiation, whereas this subset was protected 
by the addition of soy isoflavones. Interstitial macrophages 
played immunoregulatory roles in the maintenance of lung 
homeostasis and in pathologic conditions.41 Soy could poten-
tially inhibit inflammatory responses by protecting intersti-
tial macrophages. In contrast, alveolar macrophages exhibit 
a greater capacity to functionally contribute to pulmonary 
inflammation and antimicrobial defense.42 We found that soy 
isoflavones inhibited alveolar macrophage inﬁltration and 
activation induced by radiation, a possible mechanism con-
trolling inflammatory processes. These ﬁndings suggest that 
soy modulation of macrophage subset functions in response to 
radiation may play a critical role in soy-mediated radioprotec-
tive effects in lungs.
In radiation-treated lungs, our analysis of myeloid 
cells showed extensive inﬁltration of inflammatory cells at 
sites of pneumonitis, consisting of macrophages and neutro-
phils. Both types of immune cells were morphologically and 
molecularly in a status of activation. In contrast, soy supple-
mentation to radiation decreased both the inﬁltration and 
activation of myeloid cells. The influence of soy isoflavones 
on M1 and M2 macrophage polarization in irradiated lungs 
could be a mechanism of radioprotection. Macrophages pos-
sess the plasticity to respond to environmental stressors in 
tissues that functionally range from M1 proinflammatory to 
M2 immunosuppressive, anti-inflammatory phenotypes.43,44 
These two phenotypes can be distinguished by expression of 
NOS2 and Arg-1.45 Normal tissue exposed to ionizing radia-
tion generates “damage” signals and type 1 cytokines, such 
as IL-1β, IL-6, and TNF-α, that classically activate macro-
phages (M1) and drive the acute/chronic pulmonary inflam-
mation induced by radiation.46,47 M1 macrophages produce 
NOS2, which generates reactive NO species, thus promoting 
inflammation. Alternatively activated macrophages (M2) are 
important for the resolution of inflammation.48 M2 macro-
phages produce Arg-1, which generates L-ornithine from 
arginine, which is a precursor of proline, known to enhance 
collagen synthesis, thus promoting tissue repair and resolu-
tion of inflammation.43,49 Our studies now demonstrate that 
radiation induced a proinflammatory M1 phenotype in lungs 
at late time points, whereas mice receiving soy isoflavones 
and radiation switched to an anti-inflammatory M2 subtype 
with increased levels of Arg-1 and decreased NOS2. These 
data indicate that soy isoflavones supplementation to radia-
tion could result in skewing of alveolar macrophages from a 
proinflammatory M1 phenotype toward an anti-inflammatory 
M2 phenotype. These data are in agreement with soy isofla-
vones inhibition of the release of TNF-α, IL-1β, IL-6, and 
interferon-γ proinflammatory cytokines induced by radiation 
in lung tissues that promote an M1 macrophage phenotype.13
Inﬁltration and activation of neutrophils into the lung 
are key factors that occur after damage to lung tissue.23,38 
Therefore, inhibition of the inflammatory neutrophil response 
induced by radiation in the pulmonary environment may result 
in reduced host tissue damage. Our flow cytometry studies 
of lung single-cell suspensions showed that CD11b+Ly6G+ 
neutrophils were increased after radiation. Immunostaining 
conﬁrmed clusters of activated neutrophils, as conﬁrmed by 
MPO staining, in sites of pneumonitis caused by radiation. 
Treatment with soy isoflavones inhibited radiation-induced 
neutrophil inﬁltration and activation, suggesting a mechanism 
of protection from tissue damage by soy.
In summary, our preclinical study in lung suggests 
that a radioprotective mechanism of soy isoflavones could 
involve inhibition of inﬁltration and activation of macro-
phages and neutrophils in irradiated lungs. These ﬁndings 
indicate that soy isoflavones used as a complementary inter-
vention to radiotherapy for lung cancer could potentially 
reduce lung toxicity. This approach has been translated into 
an ongoing phase I clinical trial of chemoradiotherapy for 
advanced stage III NSCLC to evaluate the safety and efﬁ-
cacy of soy isoflavone supplementation.
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Erratum
Increasing Physical Activity and Exercise in Lung Cancer
Reviewing Safety, Benefits, and Application: Erratum
In regard to our recent article published in Journal of Thoracic oncology (Increasing Physical Activity and Exercise in Lung Cancer: Reviewing Safety, 
Beneﬁts, and Application), we recognized an error that needs amending.1
In the “How Much Exercise” section, we suggest that the physical activity recommendation by the American Heart Association (150 min/wk of moderate 
intensity exercise)1 is probably unattainable for most lung cancer patients. We cited Maddocks et al.’s2 2012 Letter to the Editor, “When will I get my breath 
back? Recovery time of exercise-induced breathlessness in patients with thoracic cancer.” The letter reported that lung cancer and mesothelioma patients 
have a median relief of breathlessness after 4 minutes using an Incremental Shuttle Walk Test (median of 360 m over a mean of 373 sec). We erroneously 
stated that lung cancer patients exercised 4 minutes before they became breathless.
Despite our inaccurate reference to Maddocks et al.’s2 letter, we still feel that exercise goals for healthy patients are unrealistic for most lung cancer patients. 
In 52 patients with lung cancer or mesothelioma after chemotherapy or radiotherapy, O’Driscoll et al.3 reported that 50% reported breathlessness with walk-
ing, 19% reported breathlessness with bathing, and 17% reported breathlessness with bending or talking. Granger at al.4 have shown that at diagnosis non–
small-cell lung cancer patients engage in less physical activity than their healthy counterparts, and 6-minute walk distance (6MWD) in lung cancer patients 
is lower than in healthy patients. Whereas healthy adult 6MWD is estimated at 630 m,5 and in 56 lung cancer patients, Granger et al.4 reported mean 6MWD 
of 421 m with a minimal important difference between 22 and 42 m.
We still feel that physical activity is a safe and beneﬁcial therapy for lung cancer. We apologize for our error.
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